Use of Faecalibacterium Prausnitzii Htf-f (DSM 26943) to Suppress Inflammation

Abstract

The present invention relates to medicine, particularly immunology and gastroenterology. Specifically, it relates to probiotic bacteria and extracts thereof for therapeutic use for the treatment of inflammatory disorders such as inflammatory bowel disease. Provided is a composition comprising as active ingredient Faecalibacterium prausnitzii strain HTF-F (DSM 26943) or an extract thereof comprising extracellular polymeric matrix (EPM), and an acceptable carrier, diluent or excipient. Also provided is an anti-inflammatory composition comprising EPM extracted from F. prausnitzii strain HTF-F, and a method for preparing the same.

1 . A pharmaceutical, neutraceutical or food composition comprising as active ingredient  Faecalibacterium prausnitzii  strain HTF-F (deposited with the DSMZ on Mar. 1, 2013 under the accession number DSM 26943), and an acceptable carrier, diluent or excipient. 
     
     
         2 . Composition according to  claim 1 , comprising viable cells of  Faecalibacterium prausnitzii  strain HTF-F (DSM 26943). 
     
     
         3 . Composition according to  claim 1 , comprising non-viable cells of  Faecalibacterium prausnitzii  strain HTF-F (DSM 26943). 
     
     
         4 . Composition according to any one of  claims 1 - 3 , further comprising one or more prebiotics, preferably oligosaccharides, more preferably fructooligosaccharides, pectins and/or inulin. 
     
     
         5 . Composition according to any one of  claims 1 - 4 , further comprising one or more probiotic bacteria, preferably selected from the group consisting of  Bifidobacterium, Lactobacillus, Streptococcus  and  Saccharomyces  and mixtures thereof. 
     
     
         6 . Composition according to any one of  claims 1 - 5 , being a food composition, food supplement or neutraceutical. 
     
     
         7 . Composition according to any one of  claims 1 - 5 , being a pharmaceutical composition, preferably formulated in an orally ingestible form, preferably in the form of a capsule, microcapsule, tablet, granule, powder, troche, pill, suspension or syrup. 
     
     
         8 .  F. prausnitzii  strain HTF-F (DSM 26943) for use as a medicament. 
     
     
         9 .  F. prausnitzii  strain HTF-F (DSM 26943) for use in a method for treating or preventing symptoms associated with an inflammatory disorder and/or microbiota disbalance of the gastrointestinal tract of a mammalian subject. 
     
     
         10 .  F. prausnitzii  strain HTF-F for use according to  claim 9 , wherein said subject is a human. 
     
     
         11 .  F. prausnitzii  strain HTF-F for use according to  claim 9 , wherein said subject is a domestic animal or an agricultural animal. 
     
     
         12 .  F. prausnitzii  strain HTF-F for use according to any one of  claims 8 - 11 , wherein said bacterium is formulated to be administered to a subject in a therapeutically effective amount, preferably wherein the therapeutically effective amount of the bacterium is about 10exp6 to 10exp11 CFU/day. 
     
     
         13 .  F. prausnitzii  strain HTF-F for use according to any one of  claims 8 - 12  wherein said gastrointestinal disorder is selected from the group consisting of inflammatory bowel disease, Crohn's disease, irritable bowel syndrome, coeliac disease, infectious colitis, ulcerative colitis, and any combination thereof. 
     
     
         14 . A method for producing an anti-inflammatory composition, comprising the steps of
 a) harvesting living cells of  Faecalibacterium prausnitzii  strain HTF-F (DSM 26943) and resuspending the cells in a suitable buffer, preferably PBS;   b) vortexing the resuspended cells for at least 3 minutes allowing the cell-bound extracellular polymeric matrix (EPM) to dissolve in the buffer;   c) pelleting the cells by centrifugation and harvesting the supernatant   d) adding about 4 volumes of ice-cold ethanol to the supernatant to precipitate the EPM;   e) washing the precipitated EPM with ethanol;   f) optionally followed by lyophilization.   
     
     
         15 . A synbiotic composition comprising living cells of  Faecalibacterium prausnitzii  strain HTF-F (DSM 26943) formulated with (i) riboflavin, riboflavin phosphate or a physiologically acceptable salt thereof in an amount of at least 0.05% based on the total dry weight of the composition, and (ii) cysteine, preferably present in an amount of at least 0.05% based on the total dry weight of the composition. 
     
     
         16 . Synbiotic composition according to  claim 15 , further comprising inulin or inulin-type fructo-oligosaccharides, pectin preferably in an amount of 2-10% based on the total dry weight of the composition. 
     
     
         17 . Use of  Faecalibacterium prausnitzii  strain HTF-F (DSM 26943) for the production of an anti-inflammatory composition.